LOGO
LOGO

Email This Article

REGENXBIO Reports Positive Topline Data From Phase III AFFINITY DUCHENNE Trial Of RGX-202
To Email: *
Bcc: Seperate multiple addresses with commas(,)
Your Email: *
Format :

* Denotes Required Fields